- Home
- JWN vs XENE Comparison
JWN vs XENE Comparison
Compare JWN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWN
- XENE
- Stock Information
- Founded
- JWN 1901
- XENE 1996
- Country
- JWN United States
- XENE Canada
- Employees
- JWN N/A
- XENE N/A
- Industry
- JWN Clothing/Shoe/Accessory Stores
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- JWN Consumer Discretionary
- XENE Health Care
- Exchange
- JWN Nasdaq
- XENE Nasdaq
- Market Cap
- JWN 4.0B
- XENE 3.3B
- IPO Year
- JWN N/A
- XENE 2014
- Fundamental
- Price
- JWN $24.47
- XENE $34.26
- Analyst Decision
- JWN Hold
- XENE Strong Buy
- Analyst Count
- JWN 12
- XENE 7
- Target Price
- JWN $22.45
- XENE $57.00
- AVG Volume (30 Days)
- JWN 2.9M
- XENE 459.8K
- Earning Date
- JWN 03-04-2025
- XENE 05-08-2025
- Dividend Yield
- JWN 3.11%
- XENE N/A
- EPS Growth
- JWN 112.19
- XENE N/A
- EPS
- JWN 1.74
- XENE N/A
- Revenue
- JWN $15,016,000,000.00
- XENE N/A
- Revenue This Year
- JWN $2.68
- XENE N/A
- Revenue Next Year
- JWN $1.45
- XENE $826.46
- P/E Ratio
- JWN $14.06
- XENE N/A
- Revenue Growth
- JWN 2.20
- XENE N/A
- 52 Week Low
- JWN $17.20
- XENE $33.27
- 52 Week High
- JWN $24.99
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- JWN 65.35
- XENE 38.03
- Support Level
- JWN $24.17
- XENE $33.62
- Resistance Level
- JWN $24.49
- XENE $36.25
- Average True Range (ATR)
- JWN 0.08
- XENE 1.22
- MACD
- JWN 0.02
- XENE 0.02
- Stochastic Oscillator
- JWN 96.97
- XENE 22.28
About JWN Nordstrom Inc.
Nordstrom is a fashion retailer that operates about 93 department stores and 280 off-price Nordstrom Rack stores. The company also operates both full- and off-price e-commerce sites, two clearance stores, and six Local locations. Nordstrom's largest merchandise categories are women's apparel (27% of 2023 sales), shoes (26% of 2023 sales), men's apparel (15% of 2023 sales), and beauty (13% of 2023 sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the eponymous family.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.